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for breast cancer through ex vivo
expansion and genome editing of
mammary stem cells. Using this platform,
they uncovered the functional roles of
several human cancer-associated genes
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Cancer genomics has provided an unprecedented
opportunity for understanding genetic causes of
human cancer. However, distinguishing which
mutations are functionally relevant to cancer patho-
genesis remains a major challenge. We describe
here a mammary stem cell (MaSC) organoid-based
approach for rapid generation of somatic geneti-
cally engineered mouse models (GEMMs). By using
RNAi and CRISPR-mediated genome engineering in
MaSC-GEMMs, we have discovered that inactivation
of Ptpn22 or Mll3, two genes mutated in human
breast cancer, greatly accelerated PI3K-drivenmam-
mary tumorigenesis. Using these tumor models, we
have also identified genetic alterations promoting
tumor metastasis and causing resistance to PI3K-
targeted therapy. Both Ptpn22 and Mll3 inactivation
resulted in disruption of mammary gland differentia-
tion and an increase in stem cell activity. Mechanisti-
cally, Mll3 deletion enhanced stem cell activity
through activation of the HIF pathway. Thus, our
study has established a robust in vivo platform for
functional cancer genomics and has discovered
functional breast cancer mutations.
INTRODUCTION
Breast cancer is a leading cause of death in women, with 1.7
million new cases and more than half a million deaths globally
each year (Torre et al., 2015). Complicating our efforts to
develop effective treatments, breast cancers have highly het-
erogeneous genetic makeups. Although a few genes, such as
PIK3CA and TP53, are mutated at relatively high frequencies3146 Cell Reports 16, 3146–3156, September 20, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://(30%–40%), the numerous remaining breast cancer-associated
genes are only altered at intermediate to low frequencies
(<10%), and their functions in cancer remain poorly understood
(Cancer Genome Atlas Network, 2012). Determining the func-
tions of these mutations will lead to new mechanistic under-
standing of cancer pathogenesis and help with the development
of targeted therapies that can be tailored specifically to each
patient.
Because cancer development is amultistep process controlled
bycomplex tissuemicroenvironmentandsystemic factors, study-
ing a putative cancer-related gene often requires in vivo models.
As such, genetically engineered mouse models (GEMMs) have
been a main approach for validating human cancer genes and
for dissecting their mechanisms of action (Van Dyke and Jacks,
2002). However, traditional germline GEMMs are prohibitively
costly and time-consuming for studying the large numbers of
genes mutated in human cancers. To address this issue, we
have developed a mouse mammary stem cell (MaSC)-based so-
matic GEMM platform for functional cancer genomics studies.
Using these MaSC-GEMMs, we have identified several function-
ally important breast cancer genes and shown that dysregulation
ofmammary stem/progenitor cell fate is a commonmechanismof
action for these genes.
RESULTS
Long-Term Expansion of MaSCs In Vitro
Although several methods have been established for measuring
MaSC activity in vitro (Dontu et al., 2003; Guo et al., 2012;
Shackleton et al., 2006; Spike et al., 2012; Stingl et al., 2006;
Zeng and Nusse, 2010), robust long-term expansion of MaSCs
in culture is still difficult. We previously developed an organoid
assay that can be used to specifically identify bipotent MaSCs
(Guo et al., 2012). Therefore, we optimized this system and
tested whether it can support long-term expansion of MaSCs.
To this end, we seeded CD49fhighCD61+ stem cell-enricheduthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
basal cells from CAG-EGFP transgenic mice at clonal density to
generate single-cell derived organoids. The clonality of organo-
ids formed under this condition was confirmed by mixing CAG-
EGFP cells with unlabeled cells and showing that almost all
individual organoids were of a single color (Figure S1A). We
then dissociated individual organoids and passaged them seri-
ally. These cells multiplied rapidly with an expansion rate of
100-fold per week even after 4 months in culture (Figure 1A).
During each passage,10% of the cells were capable of re-initi-
ating new organoids (Figure S1B). Additionally, the cells main-
tained a normal karyotype, suggesting that they are genetically
stable (Figure S1C).
Consistent with their stem cell origin, the organoid cells ex-
pressed the basal/MaSC markers CD49f, CD61, and PROCR
(Figures 1B and S1D; Asselin-Labat et al., 2007; Stingl et al.,
2006; Wang et al., 2015), and a fraction of them (12%) coex-
pressed the transcription factors SLUG and SOX9, which are
important for MaSC activity (Figures 1C and S1E; Guo et al.,
2012). Interestingly, the organoids contained both KRT14+ basal
andKRT8+ luminal cells organized in a partially polarized fashion,
suggesting some degree of, albeit incomplete, differentiation
(Figure 1C).
We further demonstrated that the cultured organoid cells
maintained the ability to fully regenerate mammary ductal trees
in vivo even after extended passaging (Figure 1D). Limiting dilu-
tion transplantation showed that as few as 25 organoid cells
could fully regenerate a mammary ductal tree (Figure S1F). The
frequency of mammary repopulating units was 1/170 organoid
cells, although this may underestimate the stem cell frequency
because of the difficulty of successfully transplanting a small
number of cells. The mammary outgrowths were comprised of
basal and luminal layers similar to what is observed in the endog-
enous mammary gland (Figure 1E). The regenerated glands also
underwent robust alveologenesis to produce milk-secreting
alveoli during pregnancy (Figures 1D and 1E). Furthermore, the
outgrowths recapitulated the mammary epithelial lineages of
the endogenous gland, as determined by flow cytometry (Fig-
ure 1F). These results demonstrate that our organoid culture
system can sustain the long-term expansion of transplantable
MaSCs, although they undergo some degree of differentiation
in culture, and, hence, only a subset of organoid cells are
MaSCs.
Rapid Generation of Somatic GEMMs for Breast Cancer
Using Genetically Engineered MaSCs
We next tested whether organoid cells could be used to quickly
establish somatic GEMMs for breast cancer using well estab-
lished cancer drivers (Figure S1G). We first modeled ERBB2-
driven breast cancer by transducing the cells with lentiviral vec-
tors expressing Erbb2V664E and doxycycline-inducible c-MYC
because c-MYC is often amplified or overexpressed in human
ERBB2-positive cancer (Park et al., 2005). These modified cells
regenerated elaborate mammary ductal trees in the absence of
doxycycline (Figure S1H). Upon doxycycline treatment, the out-
growths developed palpable tumors with 100% penetrance in
5 weeks and then progressed into poorly differentiated adeno-
carcinomas resembling those of transgenic ERBB2 mammary
tumor models (Figure 1G; Moody et al., 2002; Muller et al., 1988).We also modeled phosphatidylinositol 3-kinase (PI3K)-driven
cancer using organoids from a Cre-inducible, constitutively
active PIK3CA mouse strain (Pik3ca*) (Srinivasan et al., 2009).
We cultured organoids frommice carrying bothRosa26-CreERT2
and Pik3ca* alleles and then transplanted these cells into syn-
geneic C57BL/6 mice. The transplanted cells developed into
normal mammary ductal trees (Figure S1H). However, upon
administration of tamoxifen, the ductal trees developed into pro-
nounced glandular adenosis characterized by dilated ducts (Fig-
ure 1H) and progressed into overt tumors with a median onset
time of 9 months, consistent with the median onset time of
5–16months in previous germline PIK3CA tumormodels (Adams
et al., 2011; Koren and Bentires-Alj, 2013; Liu et al., 2011; Meyer
et al., 2011). Additionally, wemodeledBrca1 and Trp53 deletion-
driven neoplasia by using organoids cultured from Blg-Cre;
Brca1floxed/floxed; Trp53–/– mice, a well-established basal-like tu-
mor model (Molyneux et al., 2010). These cells developed into
mammary ductal trees with numerous hyperplastic nodules
4 months post-transplantation (Figure 1I). Thus, our MaSC-
based somatic GEMMs (MaSC-GEMMs) provide a rapid
approach for modeling tumor development of various breast
cancer subtypes.
Identification of Breast Cancer Drivers by shRNA
Screening in MaSC-GEMMs
To test the ability of our MaSC-GEMM platform to functionally
validate the role of recently identified cancer-associated muta-
tions, we selected four genes (Map2k4, Cbfb, Ptprd, and
Ptpn22) that have frequent truncating mutations or gene dele-
tions (Cancer Genome Atlas Network, 2012). This class of muta-
tions was chosen because they likely result in a loss of function
in the gene of interest, which can be modeled by small hairpin
RNA (shRNA) knockdown (KD). Furthermore, because they are
frequently co-mutated with PIK3CA (Figure S2A), we used the
aforementioned Pik3ca* model as a sensitized background to
investigate their role in mammary tumorigenesis.
We transduced Rosa26-CreERT2; Pik3ca* organoid cells with
lentiviral shRNA vectors and confirmed a KD efficiency of at least
70% for each gene (Figure S2B). The modified cells were then
transplanted into C57BL/6 mice and treated with tamoxifen
to activate Pik3ca* expression 6 weeks later (Figure S2C). We
found that both Ptpn22 and Cbfb KD significantly accelerated
PIK3CA*-driven tumor initiation, with the median onset time
shortened from 276 days in the control group to 123 and
177 days in the shPtpn22 and shCbfb groups, respectively (Fig-
ure 2A). Interestingly, Cbfb KD also greatly accelerated tumor
growth (Figure 2B). Similar to germline PIK3CA-driven mammary
tumormodels (Adams et al., 2011;Meyer et al., 2011), the control
PIK3CA* MaSC-GEMM mainly developed adenomyoepithe-
lioma and adenocarcinoma (Figures 2C and S2D). Remarkably,
Ptpn22 KD led to the formation of more aggressive spindle cell
tumors that resemble the ones formed by the Pik3ca and
Trp53 double mutant tumor model (Figures 2C and S2D; Adams
et al., 2011).
Next we investigated the role of these genes in tumor
metastasis. Although PIK3CAmutations are frequently detected
in metastatic human breast cancers, the existing PIK3CA





Figure 1. Rapid Generation of Somatic GEMMs for Breast Cancer by Ex Vivo Expansion and Modification of MaSCs
(A) Long-term expansion of MaSC organoids. Left: a representative image of organoids. Right: growth curves of two single cell-derived organoid clones.
(B) CD49f, CD61, and PROCR flow cytometric profiles of organoids.
(C) SLUG, SOX9, and cytokeratin immunostaining in organoids. The arrows indicate examples of SLUG+SOX9+ cells.
(D) Whole-mount images of mammary ductal trees regenerated by single cell-derived GFP+ organoids at the indicated passages.
(E) Immunofluorescence images of mammary ducts (left, virgin) and alveoli (right, pregnant) regenerated by organoids (passage 2).
(F) Flow cytometric profiles of mammary ductal trees regenerated by organoids (passage 8).
(G) A representative H&E image of poorly differentiated adenocarcinoma developed in Erbb2/MYCMaSC-GEMMs (with passage 3 organoids). Organoids were
transplanted into non-obese diabetic (NOD)-severe combined immunodeficiency (SCID) mice, and the mice were treated with doxycycline for 4 months.
(H) Representative images of carmine-stained mammary fat pads reconstituted by Rosa-CreERT2; Pik3ca* organoids (passages 3–5). Mice were treated with
tamoxifen 6 weeks after transplantation and then analyzed 6 weeks later. The inset shows H&E staining of the outgrowths.
(I) Representative images of carmine-stained mammary fat pads reconstituted by Blg-Cre; Brca1floxed/floxed; p53–/– organoids (passage 5). The inset shows H&E
staining of the outgrowths.
See also Figure S1.





Figure 2. Identification of Cancer Drivers by shRNA Screening in MaSC-GEMMs
(A) Kaplan-Meier survival analysis of tumor onset in Pik3ca* MaSC-GEMMs expressing the indicated shRNAs (n = 14–40). **p < 0.01, ****p < 0.0001, compared
with shCtrl by the log-rank test.
(B) Tumor growth rates of MaSC-GEMMs as shown in (A). Data are represented as mean ± SEM (n = 7–13).
(C) Percentages of tumors with various histological phenotypes in the indicated MaSC-GEMMs (n = 11–20). **p < 0.01, chi-square test.
(legend continued on next page)
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Bentires-Alj, 2013). We hypothesized that specific genetic alter-
ations are required to cooperate with PIK3CAmutations to drive
metastasis. In confirmation of our hypothesis, Ptpn22 KD signif-
icantly promoted macroscopic lung metastases (Figure 2D).
Importantly, the increased rate of metastasis was not due to an
increase in primary tumor burden because no significant differ-
ence was noted among the experimental groups (Figure S2E).
However, Cbfb KD had no effect on tumor metastasis even
though it accelerated primary tumor growth. Taken together,
our results demonstrate the power of MaSC-GEMMs because
we were able to rapidly identify several functional cancer drivers
that play distinct roles in tumor initiation, progression, and
spread.
PTPN22 Overexpression Suppresses Tumor Growth and
Metastasis
To further demonstrate the tumor-inhibitory function of PTPN22,
we expressed it via a doxycycline-inducible vector in HCC1806
human breast cancer cells because they lack PTPN22 expres-
sion (Figure S2F). Upon induction of PTPN22 expression, the
growth of HCC1806 cells was greatly inhibited in vitro (Fig-
ure S2G). Importantly, the inhibitory effect was not due to
nonspecific toxicity of PTPN22 overexpression because similar
levels of PTPN22 overexpression had no effect on the growth
of immortalized normal humanmammary epithelial cells (HMLEs)
(Figures S2F and S2G; Elenbaas et al., 2001). Furthermore,
inducing PTPN22 expression efficiently blocked the growth of
HCC1806 xenografts (Figure 2E) and their metastases (Figures
2F and S2H), supporting a tumor-suppressive role for PTPN22.
Ptpn22 and Cbfb Knockdown Confers Resistance to
PI3K-Targeted Therapy
We reasoned that our MaSC-GEMMs could also be useful as
preclinical models for determining whether certain cooperating
mutations alter the tumor response to anti-PI3K treatment. To
this end, we orthotopically transplanted small fragments of
MaSC-GEMM tumors to generate a cohort of allograft-bearing
mice for each parental tumor. As each tumor graft reached
100 mm3 in volume, mice were treated with either the vehicle
control or GDC-0941, a pan class I PI3K inhibitor that is being
developed clinically for breast cancer treatment (Folkes et al.,
2008; Liu et al., 2011). As expected, GDC-0941 greatly dimin-
ished the growth of control shRNA-expressing tumors compared
with the vehicle control (Figures 2G and S2I). However, tu-
mors derived from PIK3CA* MaSC-GEMMs expressing either
shPtpn22 or shCbfb were significantly more resistant to GDC-(D) Lung metastases in the Pik3ca* MaSC-GEMMs expressing the indicated shR
macrometastases per animal at the end point (mean ± SEM, n = 7–16). The freq
(E) Growth curve of HCC1806 xenografts expressing doxycycline (dox)-inducible
NOD-SCID mice. Three weeks after tumor onset, mice were treated with dox and
ANOVA).
(F) Lung metastasis burden of mice transplanted with Luc2-labeled HCC1806 cell
two-way ANOVA).
(G) Relative tumor volume of animals treated by GDC-0941. Each dot represents
average volume of vehicle-treated tumors that were derived from the same par
generation allografts.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
See also Figure S2.
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fractory to the treatment (Figures 2G and S2I). These results
demonstrate that Ptpn22 or Cbfb KD promotes resistance to
PI3K-targeted therapy.
Dysregulation of the Mammary Cell Fate by Ptpn22
Suppression
We further investigated the role of Ptpn22 in mammary gland
development because its KD promoted the most aggressive
tumor phenotypes among the candidate genes. The shPtpn22
organoids generated abnormal mammary ductal trees charac-
terized by pronounced hyperplasia relative to estrous-matched
controls (Figures 3A and 3B). The hyperplastic ducts had signif-
icantly more proliferating cells compared with the control (Fig-
ure 3C) and showed expansion of both luminal and basal cell
layers (Figure 3D).We further assessed the lineage differentiation
of the outgrowths by flow cytometry (Figure S3A). Although
Ptpn22 KD did not significantly alter the ratio of basal, luminal
progenitor, and mature luminal cells (Figure S3B), it did induce
a de novo population of CD49flowCD61high cells (Figure 3E). Inter-
estingly, these CD49flowCD61high cells generated solid orga-
noids resembling those of bipotent MaSCs in organoid culture,
although the exact nature of these cells needs to be fully charac-
terized in future studies (Figure 3F).
We next examined the effect of Ptpn22 KD on stem cell
activity of the organoid cells in vitro. Ptpn22 KD significantly
increased organoid-forming efficiency (Figure 3G). More strik-
ingly, although the control organoids required FGF2 to grow,
Ptpn22 KD allowed for growth under an FGF2-deficient condi-
tion, suggesting that Ptpn22 KD renders organoids independent
of certain niche factors (Figure 3G). Importantly, expressing
human PTPN22, which is not targeted by the mouse shRNA,
suppressed the FGF2-independent growth in the shPtpn22
organoids, confirming an on-target effect of shPtpn22 (Fig-
ures S3C and S3D). These results identify PTPN22 as a regulator
of mammary gland differentiation and suggest that inhibition of
PTPN22 promotes stem cell activity.
Generation of Mll3 Mutant MaSC-GEMMs Using
CRISPR-Cas9
Although the shRNA screen proved effective for cancer driver
discovery in MaSC-GEMMs, the incomplete inhibition of gene
functions by shRNAs may potentially prevent us from identi-
fying driver mutations that require complete gene inactivation.
Therefore, we used the clustered regularly interspaced short
palindromic repeat (CRISPR) technology to generate knockoutNAs. Left: representative H&E images of lung sections. Right: number of lung
uency of mice with macrometastasis is shown on each column.
PTPN22 or the control vector. 100,000 cells were orthotopically injected into
measured for tumor volume. Each curve represents one tumor (n = 8, two-way
s asmeasured by bioluminescence. Cells andmice were treated as in (E) (n = 5,
the ratio of average volume of GDC-0941-treated (for 2 weeks) tumors to the
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MaSC-GEMMs. To accomplish this, we constructed a doxycy-
cline-inducible Cas9 lentiviral vector and validated it by deleting
Trp53 inducibly in organoid cells (Figure S4A). We then applied
this approach to investigate the function of another candidate
cancer gene, MLL3 (gene symbol KMT2C), a histone methyl-
transferase that is frequently mutated in breast cancer and other
solid tumors (Cho et al., 2007; Shilatifard, 2012; Cancer Genome
Atlas Network, 2012). Intriguingly, most MLL3 mutations in
breast cancer cause truncations of key functional domains,
including the Su(var)3-9, Ezh2, trithorax (SET) methyltransfer-
ase domain, suggesting that it acts as a tumor suppressor
(Figure S4B).
We knocked out Mll3 in Rosa26-CreERT2; Pik3ca* MaSCs
because MLL3 mutations significantly co-occur with PIK3CA
mutations in human breast cancer (Figures S4B and S4C). We
were able to efficiently (10%) generate biallelic mutant orga-
noid clones (Figure 4A). Genomic DNA sequencing and western
blot revealed that these clones carried frameshift mutations re-
sulting in loss of the MLL3 protein (Figure 4B; Figure S4D). We
further confirmed that there were no mutations in nine predicted
low-probability, off-target loci in two biallelic mutant clones
(Figure S4E).
Mll3 Deletion Causes Mammary Stem Cell Expansion
and Promotes PIK3CA-Driven Tumorigenesis
We transplanted the Mll3–/– or Mll3+/+ organoid clones into
C57BL/6 mice and investigated the consequence of Mll3 dele-
tion in mammary gland development in vivo. We found that
Mll3 deletion caused severe hyperplasia (Figures 4C and 4D)
and resulted in an expansion of basal cells (Figure 4E). To further
rule out potential off-target effects of CRISPR, we targeted
the Mll3 gene with a second single guide RNA (sgRNA), this
time by transducing pooled organoid cells with the constitutive
lentiCRISPRv2 vector (Sanjana et al., 2014). These pooled Mll3
mutant organoids also generated hyperplastic ductal trees
similar to the Mll3 mutant organoid clones (Figure S4F).
Consistent with the basal expansion phenotype, we found that
Mll3–/– mammary outgrowths had a marked increase of the
CD49fhighCD61+ stem cell-enriched basal compartment and a
reduction of the CD49flowCD61– mature luminal compartment
(Figure 4F). In addition, compared withMll3+/+ cells,Mll3–/– cells
had significantly elevated organoid-forming ability, a property
specific to bipotent MaSCs (Figure 4G). To further confirm that
this phenotype is due to on-target effects of CRISPR, we
knocked downMll3 using two previously validated shRNAs (Fig-Figure 3. Dysregulation of the Mammary Cell Fate by Ptpn22 Suppress
(A) Whole-mount images of carmine-stained mammary fat pads transplanted wit
were isolated from mice in estrus 20 weeks post-transplantation.
(B) H&E images of outgrowths as generated in (A).
(C) Ki-67 immunohistochemistry (IHC) of outgrowths as generated in (A). Perc
(minimum 6 fields/outgrowth) are shown (n = 4–5).
(D) Cytokeratin immunostaining of mammary outgrowths as generated in (A).
(E) Flow cytometric analysis of mammary outgrowths formed by organoids expr
transplantation. The graph shows percentages of CD61high cells in lineage-nega
(F) Organoid structures generated by the indicated cell populations (left) and qua
(G) Organoid-forming efficiency (mean ± SEM) of the indicated cell types seeded
*p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S3.
3152 Cell Reports 16, 3146–3156, September 20, 2016ure S4G; Chen et al., 2014). Consistent with the CRISPR result,
Mll3 KD significantly increased in vitro organoid-forming activity
(Figure 4H). These data show that loss ofMll3 promotes stem cell
self-renewal and results in a differentiation block. Interestingly,
suppression of Mll3 in hematopoietic stem and progenitor cells
also impairs their differentiation (Chen et al., 2014), suggesting
that stem cell fate regulation is likely a common function of
MLL3 in various tissues.
We then examined whether Mll3 deletion cooperates with
PI3K activation to drive mammary tumorigenesis. To do so,
we regenerated mammary glands with pooled Mll3+/+; Pik3ca*
organoids and two independent Mll3–/–; Pik3ca* organoid lines
in C57BL/6 mice. Six weeks after transplantation, the mice
were treated with tamoxifen to activate Pik3ca* expression
and then monitored for tumor formation. We found that Mll3–/–
mammary glands developed tumors significantly sooner than
the control glands (Figure 4I). However, in contrast with the
shPtpn22 tumors, the Mll3–/– tumors did not metastasize.
Together, the above results demonstrate that Mll3 deletion
leads to dysregulation of mammary stem cell fate and promotes
tumorigenesis.
Activation of the HIF Pathway Mediates the Effect of
Mll3 Deletion on Stem Cell Activation
To understand themechanisms bywhichMll3 deletion promotes
stem cell activity, we compared transcription profiles of the vec-
tor control (Mll3+/+) andMll3–/– organoids (three lines for each) in
regular organoid culture by microarray and then performed gene
set enrichment analysis (GSEA) to identify pathways that are
differentially activated betweenMll3+/+ andMll3–/– cells. Interest-
ingly, five of the top ten gene sets upregulated in Mll3–/– cells
were targets of the hypoxia-inducible factor (HIF) pathway (Fig-
ures 5A and S5A). The upregulation of HIF target genes in
Mll3–/– organoids was further validated by qRT-PCR (Figure 5B).
Additionally, Mll3–/– organoids had markedly increased HIF-1a
protein levels relative to Mll3+/+ cells in normoxia (Figures 5C
and S5B). Mll3 KD by shRNAs also significantly elevated the
HIF-1a protein levels (Figure S5C). Acriflavine, a specific HIF in-
hibitor (Lee et al., 2009), efficiently blocked organoid formation in
both Mll3–/– and Mll3+/+ cells, suggesting that the HIF activity is
important for MaSC activity (Figure 5D). In addition, culturing
wild-type cells in hypoxia recapitulated the effect ofMll3 deletion
on stem cell activity (Figure 5E). These results suggest that Mll3
deletion activates the HIF pathway, which contributes to stem
cell hyper-activation.ion
h organoids expressing the indicated shRNAs (n = 6 for each group). Fat pads
entages of Ki-67+ cells in the mammary epithelium of individual outgrowths
essing the control or Ptpn22 shRNAs. Glands were analyzed 12 weeks post-
tive epithelial cells (mean ± SEM, n = 4–11).
ntification of solid organoid-forming ability (mean ± SEM) (right).






Figure 4. CRISPR-Mediated MaSC-GEMMs Reveal the Role of Mll3 in Mammary Tumorigenesis and Stem Cell Regulation
(A) RFLP assay for determining the Mll3 genotype of single cell-derived organoid clones. The wild-type amplicon can be digested by TaiI.
(B) MLL3 protein levels in organoid clones as determined by western blot.
(C) Whole-mount images of cleared mammary fat pads transplanted by Mll3+/+ (vector control) orMll3–/– (clone #2) organoids. Glands were analyzed 12 weeks
post-transplantation.
(D) H&E images of outgrowths as generated in (C)
(E) KRT14 and KRT8 immunofluorescence of outgrowths as generated in (C).
(F) Flow cytometric analysis of outgrowths generated by organoids expressing the control or Mll3 lentiCRISPRv2 vector (top). The percentages of stem/basal
(B/S), luminal progenitor (LP), and mature luminal cells (ML) in lineage-negative epithelial cells are shown (mean ± SEM, n = 3–4) (bottom).
(G) Organoid-forming efficiency of Mll3+/+ (vector control) and Mll3–/– organoid cells. Each data point represents an independent organoid line (mean ± SEM,
n = 3–4).
(legend continued on next page)





Figure 5. Activation of the HIF Pathway Me-
diates the Effect of Mll3 Deletion on Stem
Cell Activation
(A) Two representative gene sets upregulated in
Mll3–/– organoids as determined by GSEA.
(B) Relative mRNA levels of HIF target genes
in Mll3+/+ and Mll3–/– organoid lines (n = 3) as
measured by qRT-PCR. Gapdh and Hprt were
used as internal controls.
(C) HIF-1a protein levels in two independent lines
ofMll3+/+ (vector control) andMll3–/– organoids as
measured by western blot. Cells were transduced
by the lentiCRISPRv2 vectors. Histone H3 was
used as a loading control.
(D) Effect of the HIF inhibitor acriflavine (ACF) on
the organoid-forming ability of Mll3+/+ and Mll3–/–
cells. Cells were cultured with the indicated con-
centration of ACF for 7 days. Organoid-forming
efficiency was normalized to the respective DMSO
control.
(E) Effect of hypoxia on organoid-forming ability.
Mll3+/+ and Mll3–/– cells were cultured at the indi-
cated oxygen concentrations for 7 days. The data
are represented as mean ± SEM.
See also Figure S5.DISCUSSION
We report here a rapid and versatile somatic GEMM approach
for functional cancer genomics. Viral transduction of freshly iso-
lated mammary epithelial cells coupled with gland reconstitution
has been used previously to studymammary gland development
and breast cancer (Bouras et al., 2008; McCaffrey et al., 2012;(H) Organoid-forming efficiency (mean ± SEM) of cells transduced by the indicated shRNAs.
(I) Kaplan-Meier survival analysis of PIK3CA*-driven tumor onset in Mll3+/+ or Mll3–/– MaSC-GEMMs. p value
*p < 0.05, **p < 0.01, ***p < 0.001. ns, not significant.
See also Figure S4.
3154 Cell Reports 16, 3146–3156, September 20, 2016Welm et al., 2008). However, these previ-
ous methods can only maintain MaSCs
transiently in culture. Hence, it is difficult
to reliably generate complex modifica-
tions to model multigenic interactions
to recapitulate the heterogeneous genetic
makeup of human cancers. To allow
for complex modeling, we have devel-
oped a robust method for long-term
expansion of transplantable MaSCs
that allows for precise genetic modifica-
tions by selecting and screening cells
in vitro. In particular, the ability to expand
single cell-derived clones will allow
for CRISPR-based genome editing to
generate GEMMswith definedmutations.
Using MaSC-GEMMs, we have eluci-
dated the functions of multiple candidate
cancer genes at various stages of cancer
pathogenesis in a single study, demon-
strating the power of this approach. Thedata produced using our somatic mouse models suggest that
the loss-of-functionmutations of these genes identified in human
patients functionally contribute to breast cancer development.
Furthermore, our tumor models driven by patient-relevant muta-
tions provide useful preclinical models for studying tumor
responses to targeted therapy. We showed that inactivating
Ptpn22 or Cbfb can confer resistance to PI3K inhibition ins were determined by log-rank test.
PI3K-driven tumors. Determining the genetic makeup that ren-
ders tumors sensitive or resistant to specific therapy will aid
the development of effective cancer treatment. Using the rapid
MaSC-GEMM approach, it is feasible to generate a large collec-
tion of preclinical tumor models that are driven by combinations
of various cancer drivers. This will allow for a systematic investi-
gation of the mechanisms of drug response and for developing
combinatorial therapies.
Our results also revealed the role of these genes in cell fate
regulation. Emerging evidence has suggested that breast cancer
can originate from diverse lineages of mammary epithelial cells,
including stem cells and committed cell types (Lim et al., 2009;
Molyneux et al., 2010). However, it remains elusive whether
activation of endogenous stem cell properties and de novo
acquisition of such properties through cellular reprogramming
contribute to breast cancer development. We found that both
Ptpn22 KD and Mll3 deletion promote stem cell activity and
cause expansion of the stem cell-like population, although the
exact identity of these stem-like cells remain to be fully charac-
terized. Of note, recent lineage tracing studies suggest the exis-
tence of both bipotent and unipotent stem cells in the mammary
gland (Rios et al., 2014; Van Keymeulen et al., 2011). The effects
of these mutations in distinct stem cell populations also warrant
future investigation. Interestingly, PI3K activation has also been
shown recently to induce stem-like multipotency in various
mammary lineages (Koren et al., 2015; Van Keymeulen et al.,
2015). Together, these results suggest that stem cell fate dysre-




Pik3ca* mice (The Jackson Laboratory, 012343) were bred with Rosa26-
CreERT2 mice (The Jackson Laboratory, 008463) to generate the tamox-
ifen-inducible PIK3CA* model. Blg-Cre; Brca1flox/flox; p53–/– (012620) and
CAG-EGFP (003291) micewere obtained from The Jackson Laboratory. All an-
imal experiments were performed in accordance with protocols approved by
the Institutional Animal Care and Use Committee of Albert Einstein College
of Medicine.
MaSC Organoid Culture
Organoid medium was based on Advanced DMEM/F-12 (Thermo Fisher Sci-
entific) supplemented with 5% Matrigel (Corning Life Sciences, 354234), 5%
heat-inactivated fetal bovine serum (FBS) (Sigma, F2442), 10 ng/ml epidermal
growth factor (EGF) (Sigma, E9644), 20 ng/ml FGF2 (EMD Millipore, GF003),
4 mg/ml heparin (Sigma, H4784), and 5 mM Y-27632 (R&D Systems, 1254). For
organoid culture at clonal density, 200–500 cells /well were seeded in 96-well
ultra-low attachment plates (Corning Life Sciences). For quantifying orga-
noid-forming efficiency, the organoids (R100 mm in diameter) were counted
7 days after seeding. To establish clonal lines, individual organoids were
picked with P20 pipette tips and expanded. For passaging and expansion,
organoids were washed with PBS, dissociated with 0.05% trypsin/EDTA,
and seeded at 1 3 105 cells/well in 6-well plates. Cells were then passaged
every 3–4 days. Dissociated organoid cells can be frozen in calf serum con-
taining 8% DMSO and 5 mM Y-27632, and then thawed to reestablish the
culture.
Statistical Analysis
p values were calculated by unpaired t test except where otherwise specified.
All analyses were done in GraphPad Prism 6. p < 0.05 was considered
significant.Additional Procedures
The details of cleared fat pad transplantation, flow cytometry, tumor analysis,
tumor treatment, lentiviral vector cloning and transduction, antibody reagents,
immunofluorescence, immunoblot, restriction fragment-length polymorphism
(RFLP) assay, qRT-PCR, and microarray/GSEA analysis are included in the
Supplemental Experimental Procedures.
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10.1016/j.celrep.2016.08.048.
AUTHOR CONTRIBUTIONS
Z.Z. and W.G. conceived the study. Z.Z., J.C, C.W., and W.G. performed the
experiments and analyzed the data. M.O. performed the tumor histology anal-
ysis. K.G. assisted with the Mll3 mutant analysis. W.G. and Z.Z. wrote the pa-
per with input from all other authors.
ACKNOWLEDGMENTS
We thank Dulguun Amgalan for screening shRNAs and Dr. Scott Lowe for
generously providing Mll3 shRNA vectors. We are grateful to the shRNA,
Flow Cytometry, Histopathology, Analytical Imaging, and Molecular Cytoge-
netic core facilities for technical assistance (supported by Einstein Cancer
Center Support Grant P30 CA013330) and to the New York State Department
of Health (NYSTEM Program) for shared facility grant support (C029154).
This work is supported by grants from NYSTEM (C028109 and C029571),
Susan Komen for the Cure (CCR12224440), and the V Foundation for Cancer
Research. W.G. is a V Scholar. J.R.C. was supported by the 2T32GM007491-
36 Training Program in Cellular and Molecular Biology and Genetics.
Received: September 28, 2015
Revised: July 27, 2016
Accepted: August 16, 2016
Published: September 20, 2016
REFERENCES
Adams, J.R., Xu, K., Liu, J.C., Agamez, N.M., Loch, A.J., Wong, R.G., Wang,
W., Wright, K.L., Lane, T.F., Zacksenhaus, E., and Egan, S.E. (2011). Cooper-
ation between Pik3ca and p53mutations in mousemammary tumor formation.
Cancer Res. 71, 2706–2717.
Asselin-Labat, M.L., Sutherland, K.D., Barker, H., Thomas, R., Shackleton, M.,
Forrest, N.C., Hartley, L., Robb, L., Grosveld, F.G., van der Wees, J., et al.
(2007). Gata-3 is an essential regulator of mammary-gland morphogenesis
and luminal-cell differentiation. Nat. Cell Biol. 9, 201–209.
Bouras, T., Pal, B., Vaillant, F., Harburg, G., Asselin-Labat, M.L., Oakes, S.R.,
Lindeman, G.J., and Visvader, J.E. (2008). Notch signaling regulatesmammary
stem cell function and luminal cell-fate commitment. Cell Stem Cell 3,
429–441.
Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of
human breast tumours. Nature 490, 61–70.
Chen, C., Liu, Y., Rappaport, A.R., Kitzing, T., Schultz, N., Zhao, Z., Shroff,
A.S., Dickins, R.A., Vakoc, C.R., Bradner, J.E., et al. (2014). MLL3 is a haploin-
sufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25,
652–665.
Cho, Y.W., Hong, T., Hong, S., Guo, H., Yu, H., Kim, D., Guszczynski, T.,
Dressler, G.R., Copeland, T.D., Kalkum,M., andGe, K. (2007). PTIP associatesCell Reports 16, 3146–3156, September 20, 2016 3155
with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase
complex. J. Biol. Chem. 282, 20395–20406.
Dontu, G., Abdallah, W.M., Foley, J.M., Jackson, K.W., Clarke, M.F., Kawa-
mura, M.J., and Wicha, M.S. (2003). In vitro propagation and transcriptional
profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253–
1270.
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M.D., Zimonjic, D.B., Donaher,
J.L., Popescu, N.C., Hahn, W.C., and Weinberg, R.A. (2001). Human breast
cancer cells generated by oncogenic transformation of primary mammary
epithelial cells. Genes Dev. 15, 50–65.
Folkes, A.J., Ahmadi, K., Alderton, W.K., Alix, S., Baker, S.J., Box, G., Chuck-
owree, I.S., Clarke, P.A., Depledge, P., Eccles, S.A., et al. (2008). The identifi-
cation of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-
morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective,
orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer.
J. Med. Chem. 51, 5522–5532.
Guo, W., Keckesova, Z., Donaher, J.L., Shibue, T., Tischler, V., Reinhardt, F.,
Itzkovitz, S., Noske, A., Z€urrer-Ha¨rdi, U., Bell, G., et al. (2012). Slug and Sox9
cooperatively determine the mammary stem cell state. Cell 148, 1015–1028.
Koren, S., and Bentires-Alj, M. (2013). Mouse models of PIK3CA mutations:
one mutation initiates heterogeneous mammary tumors. FEBS J. 280, 2758–
2765.
Koren, S., Reavie, L., Couto, J.P., De Silva, D., Stadler, M.B., Roloff,
T., Britschgi, A., Eichlisberger, T., Kohler, H., Aina, O., et al. (2015).
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tu-
mours. Nature 525, 114–118.
Lee, K., Zhang, H., Qian, D.Z., Rey, S., Liu, J.O., and Semenza, G.L. (2009).
Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization.
Proc. Natl. Acad. Sci. USA 106, 17910–17915.
Lim, E., Vaillant, F., Wu, D., Forrest, N.C., Pal, B., Hart, A.H., Asselin-Labat,
M.L., Gyorki, D.E., Ward, T., Partanen, A., et al.; kConFab (2009). Aberrant
luminal progenitors as the candidate target population for basal tumor devel-
opment in BRCA1 mutation carriers. Nat. Med. 15, 907–913.
Liu, P., Cheng, H., Santiago, S., Raeder, M., Zhang, F., Isabella, A., Yang, J.,
Semaan, D.J., Chen, C., Fox, E.A., et al. (2011). Oncogenic PIK3CA-driven
mammary tumors frequently recur via PI3K pathway-dependent and PI3K
pathway-independent mechanisms. Nat. Med. 17, 1116–1120.
McCaffrey, L.M., Montalbano, J., Mihai, C., and Macara, I.G. (2012). Loss of
the Par3 polarity protein promotes breast tumorigenesis and metastasis.
Cancer Cell 22, 601–614.
Meyer, D.S., Brinkhaus, H., M€uller, U., M€uller, M., Cardiff, R.D., and Bentires-
Alj, M. (2011). Luminal expression of PIK3CA mutant H1047R in the mammary
gland induces heterogeneous tumors. Cancer Res. 71, 4344–4351.
Molyneux, G., Geyer, F.C., Magnay, F.A., McCarthy, A., Kendrick, H., Natrajan,
R., Mackay, A., Grigoriadis, A., Tutt, A., Ashworth, A., et al. (2010). BRCA1
basal-like breast cancers originate from luminal epithelial progenitors and
not from basal stem cells. Cell Stem Cell 7, 403–417.
Moody, S.E., Sarkisian, C.J., Hahn, K.T., Gunther, E.J., Pickup, S., Dugan,
K.D., Innocent, N., Cardiff, R.D., Schnall, M.D., and Chodosh, L.A. (2002). Con-3156 Cell Reports 16, 3146–3156, September 20, 2016ditional activation of Neu in themammary epithelium of transgenicmice results
in reversible pulmonary metastasis. Cancer Cell 2, 451–461.
Muller, W.J., Sinn, E., Pattengale, P.K., Wallace, R., and Leder, P. (1988). Sin-
gle-step induction of mammary adenocarcinoma in transgenic mice bearing
the activated c-neu oncogene. Cell 54, 105–115.
Park, K., Kwak, K., Kim, J., Lim, S., and Han, S. (2005). c-myc amplification is
associated with HER2 amplification and closely linked with cell proliferation in
tissue microarray of nonselected breast cancers. Hum. Pathol. 36, 634–639.
Rios, A.C., Fu, N.Y., Lindeman, G.J., and Visvader, J.E. (2014). In situ identifi-
cation of bipotent stem cells in the mammary gland. Nature 506, 322–327.
Sanjana, N.E., Shalem, O., and Zhang, F. (2014). Improved vectors and
genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784.
Shackleton, M., Vaillant, F., Simpson, K.J., Stingl, J., Smyth, G.K., Asselin-
Labat, M.L., Wu, L., Lindeman, G.J., and Visvader, J.E. (2006). Generation of
a functional mammary gland from a single stem cell. Nature 439, 84–88.
Shilatifard, A. (2012). The COMPASS family of histone H3K4 methylases:
mechanisms of regulation in development and disease pathogenesis. Annu.
Rev. Biochem. 81, 65–95.
Spike, B.T., Engle, D.D., Lin, J.C., Cheung, S.K., La, J., andWahl, G.M. (2012).
A mammary stem cell population identified and characterized in late embryo-
genesis reveals similarities to human breast cancer. Cell Stem Cell 10,
183–197.
Srinivasan, L., Sasaki, Y., Calado, D.P., Zhang, B., Paik, J.H., DePinho, R.A.,
Kutok, J.L., Kearney, J.F., Otipoby, K.L., and Rajewsky, K. (2009). PI3 kinase
signals BCR-dependent mature B cell survival. Cell 139, 573–586.
Stingl, J., Eirew, P., Ricketson, I., Shackleton, M., Vaillant, F., Choi, D., Li, H.I.,
and Eaves, C.J. (2006). Purification and unique properties of mammary epithe-
lial stem cells. Nature 439, 993–997.
Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A.
(2015). Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108.
Van Dyke, T., and Jacks, T. (2002). Cancer modeling in the modern era: prog-
ress and challenges. Cell 108, 135–144.
Van Keymeulen, A., Rocha, A.S., Ousset, M., Beck, B., Bouvencourt, G., Rock,
J., Sharma, N., Dekoninck, S., and Blanpain, C. (2011). Distinct stem cells
contribute to mammary gland development and maintenance. Nature 479,
189–193.
Van Keymeulen, A., Lee, M.Y., Ousset, M., Brohe´e, S., Rorive, S., Giraddi,
R.R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I., et al. (2015). Reac-
tivation of multipotency by oncogenic PIK3CA induces breast tumour hetero-
geneity. Nature 525, 119–123.
Wang, D., Cai, C., Dong, X., Yu, Q.C., Zhang, X.O., Yang, L., and Zeng, Y.A.
(2015). Identification of multipotent mammary stem cells by protein C receptor
expression. Nature 517, 81–84.
Welm, B.E., Dijkgraaf, G.J., Bledau, A.S., Welm, A.L., andWerb, Z. (2008). Len-
tiviral transduction of mammary stem cells for analysis of gene function during
development and cancer. Cell Stem Cell 2, 90–102.
Zeng, Y.A., and Nusse, R. (2010). Wnt proteins are self-renewal factors for
mammary stem cells and promote their long-term expansion in culture. Cell
Stem Cell 6, 568–577.
